JMP Securities Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $86
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Structure Therapeutics (NASDAQ:GPCR) but lowers the price target from $91 to $86.

August 09, 2024 | 6:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Structure Therapeutics but lowers the price target from $91 to $86.
The Market Outperform rating suggests continued confidence in the stock's performance, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100